MORE INFORMATION

▼
Thursday, 2 April 2026

European Parliament (EP) draft report on Psychosocial Risks at Work (PSR) as a critical opportunity to protect the wellbeing of the cancer workforce

›
The European Society for Medical Oncology (ESMO) recently unveiled a draft report on "preventing work-related psychosocial risks that c...
Wednesday, 18 March 2026

Redesigning oncology clinical trials with agentic AI

›
  Over the past few years, artificial intelligence (AI) has placed an increasing role in cancer research. AI tools "can be used to help...
Thursday, 12 March 2026

New survey highlights the role of clinical practice guidelines to improve care for patients with rare cancers

›
 Results from a recent ESMO (European Society for Medical Oncology) and EURACAN (European Reference Network to Cancers) had led to a "c...
Wednesday, 4 March 2026

Overall survival not substantially improved with CDK4/6 inhibitors used in first- compared with second-line treatment in Patients with HR-positive, HER2-negative advanced breast cancer

›
 Findings from SONIA, a phase III Dutch study comparing "the sequence of an aromatase inhibitor plus CDK4/6 inhibitor as first-line tre...
Wednesday, 25 February 2026

Research unlocks insights into lung cancer evolution from electronic medical records

›
 A recently completed study at the University Hospital of Toulouse, France emphasized the benefits of a "domain-specific natural langua...
Wednesday, 18 February 2026

Worse survival among patients diagnosed with cancer during first 2 years of the COVID-19 pandemic

›
A recently published U.S. population-based cohort study found "significant reductions in 1-year cause-specific survival rates among pat...
Thursday, 12 February 2026

Trustworthy and explainable AI – a key to equitable oncology

›
Trustworthiness of artificial intelligence (AI) applications and validating data analysis in cancer care was recently discussed at the ESMO ...
Thursday, 5 February 2026

RAS inhibition in pancreatic cancer

›
 The Experimental Oncology Group at the National Research Centre (CNIO) in Madrid has recently unveiled findings from genetically engineered...
Friday, 30 January 2026

Structured exercise enters ESMO guidelines for colon cancer as recommended treatment

›
 The European Society of Medical Oncology (ESMO) has released an update to their colon cancer guidelines, whereby "physical activity, w...
Thursday, 22 January 2026

European parliament adopts its position on the Critical Medicines Act, strengthening security of cancer care in Europe

›
 The European Parliament recently adopted first-reading of the Critical Medicines Act, expanding "collaborative procurement and solidar...
Tuesday, 6 January 2026

Biological mechanism enabling breast cancer to spread to the brain uncovered

›
Researchers from the Gray Faculty of Medical and Health Sciences in Tel Aviv, in partnership with researchers in 14 laboratories in Israel, ...
Wednesday, 10 December 2025

Grey Horizon postings will resume week of January 5, 2026.

›
 To all Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume the week of January 5, 2026.  Season...

Neoadjuvant immunotherapy and understanding anticancer immunity

›
 Study results currently being presented at the ESMO Immuno-Oncology Congress (held in London, England, December 10-12, 2025) showcase the r...
Friday, 5 December 2025

Going beyond protocol is key for young people with cancer

›
 Recently, at the ESMO Asia Congress 2025, emphasis was placed on the diagnosis of cancer in adolescents and young adults (AYA), which ...
Wednesday, 19 November 2025

ESMO Publishes First-Ever Guidance on Validation Requirements for AI-Based Biomarkers in Oncology

›
 The European Society for Medical Oncology (ESMO) has released the Basic Requirements for AI-Based Biomarkers in Oncology (EBAI) framework, ...
Wednesday, 12 November 2025

ESMO launches first congress on artificial intelligence and digital oncology: a milestone in shaping the future of cancer care

›
The European Society for Medical Oncology (ESMO) recently launched the inaugural Congress on Artificial Intelligence and Digital Oncology, t...
Friday, 7 November 2025

Rucaparib monotherapy provides long-term benefit as first-line maintenance for patients with advanced ovarian cancer with and without HRD

›
 Results of ATHENA-MONO/GOG-3020/ENGOT-ov45, a phase III trial investigating rucaparib as a monotherapy in first-line maintenance treatment ...
Thursday, 30 October 2025

Antitumour activity of patritumab deruxtecan in heavily pretreated patients with active brain metastases of breast cancer and NSCLC

›
 Results from TUXEDO-3, a prospective multicentre open-label single-arm multicohort phase II study were recently published on The Lancet Onc...
Thursday, 23 October 2025

Rethinking the limits of tissue-agnostic cancer therapy

›
A recent editorial published in the ESMO Daily Reporter raises questions about the impact of precision medicine in personalized cancer care,...
Thursday, 16 October 2025

Thymic health linked to cancer patients’ response to immunotherapy

›
A recent international study focused on immune checkpoint inhibitor treatment has shown that higher thymic health was associated with a 35% ...
Wednesday, 8 October 2025

Increased risk of haematologic malignancies among children and adolescents exposed to radiation from medical imaging

›
 Findings from Risk of Pediatric and Adolescent Cancer Associated with Medical Imaging (RIC) a cohort study of 3 700 000 children from Canad...
Wednesday, 1 October 2025

Study presents an AI-guided approach to target cancer antigens

›
 A recent study published in Science  provides proof-of-concept that "generative artificial intelligence can offer a valid alternative ...
Wednesday, 24 September 2025

De-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell carcinoma

›
A recently published phase III trial in Lancet Oncology, lower doses of adjuvant radiotherapy plus docetaxel "were associated with redu...
Wednesday, 17 September 2025

ESMO campaigns against the use of ‘Low-Alcohol’ labelling in response to council agreement on EU’s wine package

›
The European Society for Medical Oncology (ESMO) in partnership with the European Alliance on Alcohol (EHAA) has issued a statement against ...
Wednesday, 10 September 2025

ESMO urges EU policymakers to protect the wellbeing of the oncology workforce

›
 The European Society for Medical Oncology (ESMO) has produced a new health workforce crisis plan, stressing "the urgent need for dedic...
Wednesday, 3 September 2025

Arsenic trioxide in combination with all-trans retinoic acid for the treatment of newly diagnosed patients with high-risk APL

›
 Results from APOLLO, a randomized phase III study, indicated that a "near-chemotherapy free treatment of arsenic trioxide in combinati...
Tuesday, 19 August 2025

Blog postings will resume in September 2025

›
 Dear Grey Horizon readers,  Thank you for your continued support of this blog.  Postings will resume in September 2025.  

No survival benefit from adding adjuvant chemotherapy to endocrine therapy in older women with a genomic grade index high-risk ER-positive, HER2-negative breast cancer

›
Findings from ASTER 70s, a phase III randomized superiority study conducted on women 70 years or older "with a genomic grade index (GGI...
Thursday, 14 August 2025

ESMO joins the European Health Alliance on Alcohol (EHAA) to reduce preventable cancer cases linked to alcohol use

›
The European Society for Medical Oncology (ESMO) has joined the European Health Alliance on Alcohol (EHAA).  Classified as a group 1 carcino...
Thursday, 7 August 2025

Savolitinib plus osimertinib show a high response in EGFR-mutated NSCLC progressed on first-line osimertinib due to MET-driven resistance mechanisms

›
 Results of SAVANNAH, a phase II study comprised of "one of the largest datasets evaluating an oral MET tyrosine kinase inhibitor in EG...